Influences of Chymase and Angiotensin I-Converting Enzyme Gene Polymorphisms on Gastric Cancer Risks in Japan

Backgrounds and Aims: The renin-angiotensin system plays an important role in homeostasis. Angiotensin II, which is generated by chymase and angiotensin I-converting enzyme (ACE), controls blood pressure as well as angiogenesis and cell proliferation. The aim of this study was to clarify the association of the chymase gene (CMA/B) and ACE polymorphisms with susceptibility to gastric cancer and peptic ulcer. Methods: We assessed CMA/B A/G and ACE insertion/deletion (I/D) polymorphisms in H. pylori-positive gastric cancers (n = 119), gastric ulcers (n = 127), and duodenal ulcers (n = 105), and controls (n = 294) consisting of H. pylori-positive gastritis alone (n = 162) and H. pylori-negative subjects (n = 132) by PCR methods. Results: In CMA/B polymorphism, the age- and sex-adjusted odds ratios (OR) of A/A and A/G genotypes relative to the G/G genotype for gastric cancer risk were 7.115 (95% confidence interval, 1.818-27.845) and 1.956 (95% confidence interval, 1.137-3.366), respectively. There was an increased risk for gastric ulcer in the A/A genotype (OR, 3.450; 1.086-10.960). However, there was no association between ACE polymorphism and susceptibility to gastric cancer and peptic ulcer. In allele combination analysis of CMA/B and ACE polymorphisms, the A/I allele combinations (CMA/B G/A or A/A and ACE I/I genotype) significantly increased the risk of gastric cancer development (OR, 4.749, 2.050-11.001) compared with the G/I allele combinations (CMA/B G/G and ACE I/I genotype). Conclusions: The CMA/B polymorphism was associated with an increased risk for gastric cancer and gastric ulcer development. The genotyping test of the renin-angiotensin system could be useful for the screening of individuals with higher risks of gastric cancer and gastric ulcer. (Cancer Epidemiol Biomarkers Prev 2006;15(10):1929–34)

[1]  Y. Goto,et al.  The ACE gene polymorphism is associated with the incidence of gastric cancer among H. pylori seropositive subjects with atrophic gastritis. , 2005, Asian Pacific journal of cancer prevention : APJCP.

[2]  D. Slaaf,et al.  Angiotensin II stimulates angiogenesis in the chorio-allantoic membrane of the chick embryo. , 1991, European journal of pharmacology.

[3]  H. Urata,et al.  Cellular localization and regional distribution of an angiotensin II-forming chymase in the heart. , 1993, The Journal of clinical investigation.

[4]  T. Matsuo,et al.  Mast cell chymase expression in Helicobacter pylori‐associated gastritis , 2003, Histopathology.

[5]  HighWire Press,et al.  Cancer epidemiology biomarkers & prevention , 1991 .

[6]  P Corvol,et al.  An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. , 1990, The Journal of clinical investigation.

[7]  S. Takai,et al.  Suppression of basic fibroblast growth factor‐induced angiogenesis by a specific chymase inhibitor, BCEAB, through the chymase‐angiotensin‐dependent pathway in hamster sponge granulomas , 2002, British journal of pharmacology.

[8]  R. P. Blankfield,et al.  Helicobacter pylori infection and the development of gastric cancer. , 2001, The New England journal of medicine.

[9]  S. Takai,et al.  Characterization of chymase from human vascular tissues. , 1997, Clinica chimica acta; international journal of clinical chemistry.

[10]  H. Sugimura,et al.  Poor metabolizer genotype status of CYP2C19 is a risk factor for developing gastric cancer in Japanese patients with Helicobacter pylori infection , 2005, Alimentary pharmacology & therapeutics.

[11]  H. Sugimura,et al.  Different effects of polymorphisms of tumor necrosis factor‐alpha and interleukin‐1 beta on development of peptic ulcer and gastric cancer , 2007, Journal of gastroenterology and hepatology.

[12]  P. Malfertheiner,et al.  The Number of Lymph Node Metastases in Gastric Cancer Correlates with the Angiotensin I–Converting Enzyme Gene Insertion/Deletion Polymorphism , 2005, Clinical Cancer Research.

[13]  J. Ferlay,et al.  Estimates of the worldwide mortality from 25 cancers in 1990 , 1999, International journal of cancer.

[14]  C. Nahmias,et al.  Angiotensin receptors: a new role in cancer? , 2005, Trends in Endocrinology & Metabolism.

[15]  L. Murray,et al.  Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? , 1998, The Lancet.

[16]  T. Imanishi,et al.  Angiotensin II potentiates vascular endothelial growth factor-induced proliferation and network formation of endothelial progenitor cells. , 2004, Hypertension research : official journal of the Japanese Society of Hypertension.

[17]  M. Miyazaki,et al.  Marked species-difference in the vascular angiotensin II-forming pathways: humans versus rodents. , 1993, Japanese journal of pharmacology.

[18]  A. Hofman,et al.  Angiotensin-Converting Enzyme Gene Insertion/Deletion Polymorphism and Breast Cancer Risk , 2005, Cancer Epidemiology Biomarkers & Prevention.

[19]  K. Ishikawa,et al.  Clinical Application of Serum Pepsinogen I and II Levels for Mass Screening to Detect Gastric Cancer , 1993, Japanese journal of cancer research : Gann.

[20]  P. Malfertheiner,et al.  The Angiotensin I–Converting Enzyme Gene Insertion/Deletion Polymorphism Is Linked to Early Gastric Cancer , 2005, Cancer Epidemiology Biomarkers & Prevention.

[21]  D. Graham,et al.  Relationship of Helicobacter pylori to serum pepsinogens in an asymptomatic Japanese population. , 1992, Gastroenterology.

[22]  J. Egido,et al.  Inflammation and angiotensin II. , 2003, The international journal of biochemistry & cell biology.

[23]  P. Laurén,et al.  THE TWO HISTOLOGICAL MAIN TYPES OF GASTRIC CARCINOMA: DIFFUSE AND SO-CALLED INTESTINAL-TYPE CARCINOMA. AN ATTEMPT AT A HISTO-CLINICAL CLASSIFICATION. , 1965, Acta pathologica et microbiologica Scandinavica.

[24]  Y. Shiratori,et al.  The Effect of Eradicating Helicobacter Pylori on the Development of Gastric Cancer in Patients with Peptic Ulcer Disease , 2005, The American Journal of Gastroenterology.

[25]  Yung‐Chie Lee,et al.  Association of Angiotensin-Converting Enzyme Insertion/Deletion Polymorphism With Serum Level and Development of Pulmonary Complications Following Esophagectomy , 2005, Annals of surgery.

[26]  R Kreutz,et al.  A prospective evaluation of an angiotensin-converting-enzyme gene polymorphism and the risk of ischemic heart disease. , 1995, The New England journal of medicine.

[27]  S. Komune,et al.  Effects of the angiotensin-I converting enzyme inhibitor perindopril on tumor growth and angiogenesis in head and neck squamous cell carcinoma cells , 2004, Journal of Cancer Research and Clinical Oncology.

[28]  Y. Nagashima,et al.  Angiotensin II receptor blocker shows antiproliferative activity in prostate cancer cells: a possibility of tyrosine kinase inhibitor of growth factor. , 2003, Molecular cancer therapeutics.

[29]  M. Carrington,et al.  Interleukin-1 polymorphisms associated with increased risk of gastric cancer , 2000, Nature.

[30]  D. Pinto,et al.  Linkage of angiotensin I‐converting enzyme gene insertion/deletion polymorphism to the progression of human prostate cancer , 2004, The Journal of pathology.

[31]  T. Wienker,et al.  Angiotensin-converting enzyme and heart chymase gene polymorphisms in hypertrophic cardiomyopathy. , 1996, The American journal of cardiology.

[32]  L. Tiret,et al.  Identification of new polymorphisms of the angiotensin I-converting enzyme (ACE) gene, and study of their relationship to plasma ACE levels by two-QTL segregation-linkage analysis. , 1996, American journal of human genetics.

[33]  T. Wienker,et al.  Chymase gene locus is not associated with myocardial infarction and is not linked to heart size or blood pressure. , 1998, The American journal of cardiology.

[34]  B. Henderson,et al.  Genetic variation in angiotensin I-converting enzyme (ACE) and breast cancer risk: the multiethnic cohort. , 2003, Cancer research.

[35]  Woon-Puay Koh,et al.  Angiotensin I-converting enzyme (ACE) gene polymorphism and breast cancer risk among Chinese women in Singapore. , 2003, Cancer research.

[36]  Philippe Amouyel,et al.  Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction , 1992, Nature.

[37]  A. Muscella,et al.  Angiotensin II activates extracellular signal regulated kinases via protein kinase C and epidermal growth factor receptor in breast cancer cells , 2003, Journal of cellular physiology.

[38]  S. Takai,et al.  Expression of chymase‐positive cells in gastric cancer and its correlation with the angiogenesis , 2006, Journal of surgical oncology.

[39]  J. Goedert,et al.  Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms. , 2003, Gastroenterology.

[40]  W. Grzeszczak,et al.  Angiotensin I-converting enzyme gene polymorphisms: relationship to nephropathy in patients with non-insulin dependent diabetes mellitus. , 1998, Journal of the American Society of Nephrology : JASN.

[41]  Y. Oda,et al.  Relationship between genetic polymorphisms of drug-metabolizing enzymes (CYP1A1, CYP2E1, GSTM1, and NAT2), drinking habits, histological subtypes, and p53 gene point mutations in Japanese patients with gastric cancer , 2004, Journal of Gastroenterology.

[42]  R. Graham,et al.  Cloning of the gene and cDNA for human heart chymase. , 1991, The Journal of biological chemistry.

[43]  Sattler,et al.  Effect of angiotensin II and telmisartan, an angiotensin1 receptor antagonist, on rat gastric mucosal blood flow , 1999, Alimentary pharmacology & therapeutics.